PARK syndrome

PARK syndrome (or Parkinsonism syndrome with dopamine deficiency) is a group of neurodegenerative diseases that manifest symptoms similar to Parkinson's disease, but differ in etiology, pathogenesis and clinical features. The main characteristics of PARK syndrome include progressive impairment of motor function, including temporary slowness of movement (bradykinesia), muscle rigidity and tremor. Pathological changes observed in this syndrome may be associated with the peculiarities of the mechanism of interaction of neurotransmitters in the brain, as well as with the addition of various intracranial changes and oxidative stress activity. Given the complex etiology, various genetic and acquired factors are attributed to this group of syndromes, emphasizing the importance of taking them into account when developing diagnostic and therapeutic methods.

History of the disease and interesting historical facts

PARK syndrome was first described in the early 1990s, when extensive research into parkinsonism began. However, the manifestations of parkinsonism have been known since ancient times. In the works of Hippocrates and other ancient doctors, one can find descriptions of diseases similar in symptoms to modern forms of parkinsonism. It is interesting that the famous French neurologist Jean Martin Charcot made a significant contribution to understanding the various types of parkinsonism, classifying them and creating a basis for further study. In modern times, special attention is paid to the genetic aspects of this syndrome, which has led to the identification of various mutations responsible for the development of neurological disorders.

Epidemiology

According to statistics, the prevalence of PARK syndrome varies depending on the region and the genetic predisposition of the population. For example, the highest number of registered cases is observed in countries with a high level of population aging and developed medical care. It is estimated that up to 1% of the population over 60 years old may suffer from one of the types of PARK syndrome. Moreover, the data show that men are more susceptible to this syndrome than women, which also raises questions about possible hormonal and genetic factors influencing the incidence of the disease.

Genetic predisposition to this disease

The genetic component plays a key role in the etiology of PARK syndrome. The main genes associated with various forms of primary parkinsonism are PARKIN, PINK1 and DJ-1. Mutations in these genes can lead to disruption of mitochondrial function processes and an increase in oxidative stress, which ultimately contributes to neurodegeneration. In addition, studies show that some polymorphisms in genes regulating neurotransmitter transmission may also play an important role in predisposition to parkinsonism. However, it is important to note that not all forms of PARK syndrome have a clear hereditary component - many of them arise as a result of a combination of genetic and environmental factors.

Risk factors for the development of this disease

There are several risk factors that contribute to the development of PARK syndrome, which can be classified as physical, chemical and environmental.

• Physical factors: Age is the most significant risk – the risk increases with age, especially for people over 60 years of age.
• Chemical factors: Certain substances, such as pesticides, are known to increase the risk of developing Parkinson's disease.
• Environmental factors: Living in areas with high levels of environmental pollution is also associated with increased risk, as is occupational exposure (e.g. working in agriculture or factories).

Long-term use of certain medications, such as antipsychotics, can also trigger Parkinson-like symptoms.

Diagnosis of this disease

Diagnosis of PARK syndrome includes several key stages aimed at identifying the main symptoms and excluding other diseases.

• Main symptoms: Patients often present with complaints such as bradykinesia, rigidity, postural disturbances and tremor. The presence of at least three of these symptoms may raise suspicion of parkinsonism.
• Laboratory tests: Blood tests can help rule out other causes of movement disorders, such as vitamin deficiencies or inflammatory processes.
• Radiological examinations: MRI and CT scans of the brain are used to visualize structures and help rule out tumors or other diseases.
• Other diagnostic tests: Electromyography (EMG) and neuropsychological function tests may help clarify the diagnosis.
• Differential diagnosis: It is necessary to exclude other forms of parkinsonism, such as Parkinson's disease, Parkinson's syndrome and secondary parkinsonisms.

Treatment

Treatment of PARK syndrome involves a comprehensive approach, including pharmacological and non-drug methods.

• General treatment: Treatment aims to reduce symptoms and improve the patient's quality of life. Initial approaches often include education and lifestyle recommendations.
• Pharmacological treatment: In the early stages of the disease, drugs that increase dopamine levels (eg, levodopa and dopamine agonists) are used. In later stages, drugs that reduce oxidative stress may be added.
• Surgical treatment: In selected cases, surgery such as stereotactic surgery may be considered to reduce symptoms, but this is rare in PARK syndrome.
• Other treatments: Physical therapy, psychotherapy, and alternative medicine may also be helpful in reducing symptoms.

List of medications used to treat this disease

• Levodopa
• Dopamine agonists (bromocriptine, pramipexole)
• Injectable drugs (apomorphine)
• MAO-B inhibitors (rizagiline, selegiline)
• Antioxidants (N-acetylcysteine)

Disease monitoring

Disease monitoring plays an important role in clinical practice. Correct assessment of the disease stage and its dynamics allows for treatment adjustments, confirming its effectiveness. Regular follow-up examinations are recommended:

• Follow-up visits should be every 3-6 months with subsequent assessment of motor and non-motor symptoms.
• Prognosis: The prognosis depends on the age group and genetic factors, in some cases the disease develops quickly, in others slowly.
• Complications: In the long term, dementia, depressive syndromes and motor dysfunction may develop, which significantly worsens the patient’s quality of life.

Age-related features of the disease

PARK syndrome in elderly patients may have vivid manifestations against the background of age-related decline in body functions. In young people, the disease may manifest itself differently - often with less pronounced symptoms, but with a faster deterioration of the condition.

• Age up to 50 years: Symptoms may be mild in places, and progression is slower.
• Age 50 to 70 years: A more pronounced clinical picture is observed, which requires active intervention.
• Age over 70 years: Comorbid conditions are often present, which complicates treatment.

Questions and Answers

• What is PARK syndrome? It is a group of neurodegenerative diseases characterized by movement and dysfunction of dopamine in the brain.
• How is PARK syndrome diagnosed? The diagnosis is made on the basis of clinical symptoms, laboratory and radiological studies, and by excluding other diseases.
• What are the main treatments for PARK syndrome? The main treatment methods include pharmacotherapy using dopamine drugs, as well as rehabilitation therapy.
• What are the risk factors for developing PARK syndrome? The main risk factors include age, exposure to toxins, genetic predisposition and other exogenous causes.
• How does the clinical picture change with age? In older people, the disease tends to progress more quickly, while in the younger population it may progress slowly.